Outcomes measures in idiopathic intracranial hypertension
- PMID: 34047224
- DOI: 10.1080/14737175.2021.1931127
Outcomes measures in idiopathic intracranial hypertension
Abstract
Introduction: Idiopathic intracranial hypertension is a condition characterized by raised intracranial pressure, papilledema, and normal neuroimaging (aside from radiological signs of raised intracranial pressure). Symptoms of idiopathic intracranial hypertension include chronic headaches and for some, visual loss. New treatments are unmet clinical needs.Areas covered: The aim of this review is to present the evidence base and considered opinion on outcome measures to determine successful management of idiopathic intracranial hypertension.Expert opinion: Less invasive measures of disease activity such as optical coherence tomography will continue to grow in this field, both as a measure of papilledema, and potentially as a surrogate for intracranial pressure and visual function. As a highly disabling aspect of the disease is headache, treatment outcomes for headache morbidity need to be appropriately chosen and standardized to allow comparison between trials.
Keywords: Idiopathic intracranial hypertension; headache; intracranial pressure; obesity; optical coherence tomography; papilledema; pseudotumour cerebri; randomized control trial; vision and weight loss.
Similar articles
-
Current and emerging diagnostic and management approaches for idiopathic intracranial hypertension.Expert Rev Neurother. 2023 May;23(5):457-466. doi: 10.1080/14737175.2023.2206567. Epub 2023 Apr 28. Expert Rev Neurother. 2023. PMID: 37114519 Review.
-
Pediatric Intracranial Hypertension: A Spotlight on Imaging, the Idiopathic Intracranial Hypertension Treatment Trial, and COVID-19 Associated Cases.Semin Pediatr Neurol. 2021 Dec;40:100922. doi: 10.1016/j.spen.2021.100922. Epub 2021 Sep 4. Semin Pediatr Neurol. 2021. PMID: 34749916 Review.
-
The Pseudotumor Cerebri Syndrome.Neurol Clin. 2024 May;42(2):433-471. doi: 10.1016/j.ncl.2024.02.001. Neurol Clin. 2024. PMID: 38575259 Review.
-
[Treatment of idiopathic intracranial hypertension].Zhonghua Yan Ke Za Zhi. 2016 Dec 11;52(12):948-951. doi: 10.3760/cma.j.issn.0412-4081.2016.12.016. Zhonghua Yan Ke Za Zhi. 2016. PMID: 27998460 Review. Chinese.
-
Idiopathic intracranial hypertension: Update on diagnosis and management.Clin Med (Lond). 2020 Jul;20(4):384-388. doi: 10.7861/clinmed.2020-0232. Clin Med (Lond). 2020. PMID: 32675143 Free PMC article.
Cited by
-
Author Response: Association of Amount of Weight Lost After Bariatric Surgery With Intracranial Pressure in Women With Idiopathic Intracranial Hypertension.Neurology. 2023 Mar 14;100(11):543. doi: 10.1212/WNL.0000000000207120. Neurology. 2023. PMID: 36914270 Free PMC article. No abstract available.
-
Fulminant Idiopathic Intracranial Hypertension Should Be Redefined Without a Time Limited Definition: In reply to: Characterisation and visual outcomes of fulminant idiopathic intracranial hypertension: a narrative review.Neuroophthalmology. 2024 Apr 19;48(6):441-443. doi: 10.1080/01658107.2024.2337165. eCollection 2024. Neuroophthalmology. 2024. PMID: 39583026 Free PMC article. No abstract available.
-
A randomized sequential cross-over trial evaluating five purportedly ICP-lowering drugs in idiopathic intracranial hypertension.Headache. 2025 Feb;65(2):258-268. doi: 10.1111/head.14897. Epub 2025 Jan 24. Headache. 2025. PMID: 39853738 Free PMC article. Clinical Trial.
-
A Neuro-Ophthalmologist's Guide to Advances in Intracranial Pressure Measurements.Eye Brain. 2023 Sep 27;15:113-124. doi: 10.2147/EB.S404642. eCollection 2023. Eye Brain. 2023. PMID: 37790122 Free PMC article. Review.
-
The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial.Brain. 2023 May 2;146(5):1821-1830. doi: 10.1093/brain/awad003. Brain. 2023. PMID: 36907221 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials